A Phase Ii Study of Bibw 2992, a Novel Irreversible Dual Egfr and Her2 Tyrosine Kinase Inhibitor (Tki), in Patients with Adenocarcinoma of the Lung and Activating Egfr Mutations after Failure of One Line of Chemotherapy (Lux-Lung 2)

腫瘤醫學研究所YANG, CHIH-HSINCHIH-HSINYANG2011-06-242018-07-092011-06-242018-07-092009http://ntur.lib.ntu.edu.tw//handle/246246/235711en-USA Phase Ii Study of Bibw 2992, a Novel Irreversible Dual Egfr and Her2 Tyrosine Kinase Inhibitor (Tki), in Patients with Adenocarcinoma of the Lung and Activating Egfr Mutations after Failure of One Line of Chemotherapy (Lux-Lung 2)